The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correspondence
PreviousPrevious
Volume 349:1002-1004 September 4, 2003 Number 10
NextNext

Heart Failure

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-Related Article
by Jessup, M.
-PubMed Citation
To the Editor: In their article on heart failure (May 15 issue),1 Jessup and Brozena do not discuss heart transplantation, which has become a mainstay of therapy for patients with end-stage heart disease. Considerable effort on behalf of clinicians and researchers has been directed toward increasing the availability of donor hearts and reducing perioperative morbidity and mortality. For example, the introduction of interleukin-2–receptor antibodies has been associated with a decrease in the frequency of acute rejection.2 Similarly, it has been shown that ABO-incompatible heart transplantation can be performed safely in infants, thereby markedly reducing mortality among children with end-stage heart . . . [Full Text of this Article]



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.